Axon Enterprise (NASDAQ:AXON – Get Rating) had its price target lowered by equities researchers at Credit Suisse Group from $169.00 to $134.00 in a research note issued to investors on Thursday, The Fly reports. Credit Suisse Group's target price suggests a potential upside of 44.76% from the company's current price.
AXON has been the topic of several other research reports. StockNews.com raised Axon Enterprise from a "hold" rating to a "buy" rating in a research note on Saturday, June 18th. Morgan Stanley downgraded Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 target price on the stock. in a research note on Monday, May 23rd. Robert W. Baird cut their target price on Axon Enterprise from $145.00 to $125.00 in a research note on Wednesday, May 11th. Northland Securities cut their target price on Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. Finally, JMP Securities reissued a "buy" rating and issued a $195.00 price objective on shares of Axon Enterprise in a research note on Wednesday, June 1st. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Axon Enterprise presently has an average rating of "Buy" and an average target price of $169.00.
Get Axon Enterprise alerts:Shares of AXON opened at $92.57 on Thursday. The firm has a market cap of $6.57 billion, a price-to-earnings ratio of 178.02 and a beta of 0.61. The stock has a 50 day moving average of $94.73 and a 200-day moving average of $116.90. The company has a current ratio of 2.43, a quick ratio of 2.18 and a debt-to-equity ratio of 0.02. Axon Enterprise has a 52 week low of $82.49 and a 52 week high of $209.00.
Axon Enterprise (NASDAQ:AXON – Get Rating) last issued its earnings results on Tuesday, May 10th. The biotechnology company reported $0.76 EPS for the quarter. Axon Enterprise had a return on equity of 3.90% and a net margin of 4.62%. The company had revenue of $256.43 million during the quarter, compared to analyst estimates of $233.57 million. During the same quarter last year, the firm earned ($0.75) EPS. The business's revenue was up 31.5% on a year-over-year basis. On average, sell-side analysts predict that Axon Enterprise will post 1.35 earnings per share for the current fiscal year.In other news, Director Mark W. Kroll sold 3,159 shares of the company's stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total value of $324,808.38. Following the sale, the director now directly owns 13,691 shares in the company, valued at approximately $1,407,708.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.90% of the company's stock.
Hedge funds have recently added to or reduced their stakes in the company. BerganKDV Wealth Management LLC grew its position in Axon Enterprise by 50.2% during the 2nd quarter. BerganKDV Wealth Management LLC now owns 2,554 shares of the biotechnology company's stock worth $238,000 after acquiring an additional 854 shares during the last quarter. Private Advisor Group LLC grew its position in Axon Enterprise by 6.0% during the 2nd quarter. Private Advisor Group LLC now owns 3,665 shares of the biotechnology company's stock worth $341,000 after acquiring an additional 207 shares during the last quarter. Handelsinvest Investeringsforvaltning grew its position in Axon Enterprise by 9.6% during the 2nd quarter. Handelsinvest Investeringsforvaltning now owns 54,800 shares of the biotechnology company's stock worth $5,106,000 after acquiring an additional 4,800 shares during the last quarter. State of Alaska Department of Revenue grew its position in Axon Enterprise by 5.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,191 shares of the biotechnology company's stock worth $949,000 after acquiring an additional 555 shares during the last quarter. Finally, Moody National Bank Trust Division bought a new stake in Axon Enterprise during the 2nd quarter worth approximately $1,351,000. Institutional investors own 72.06% of the company's stock.
Axon Enterprise Company Profile (Get Rating)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.